BAMS
AST

Bellevue Asset Management (Switzerland)’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Bellevue Asset Management (Switzerland)’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		$7K Hold
1,875
– – ﹤0.01% 126
2015
Q3 		$7K Hold
1,875
– – ﹤0.01% 132
2015
Q2 		$9K Hold
1,875
– – ﹤0.01% 138
2015
Q1 		$13K Buy
+1,875
New +$9.29K ﹤0.01% 140

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s AST Position: Q4 2015 in Review

Bellevue Asset Management (Switzerland) held its Asterias Biotherapeutics Inc. Series A (AST) position steady in Q4 2015 at 1,875 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #126.

Bellevue Asset Management (Switzerland) first reported a position in AST in Q1 2015 and has held it in 4 quarters since. The position peaked at $13K in Q1 2015. 56 funds tracked by Wall St. Rank hold AST as of Q4 2015.

  • Bellevue Asset Management (Switzerland) held 1,875 shares of Asterias Biotherapeutics Inc. Series A worth $7K as of Q4 2015.
  • Bellevue Asset Management (Switzerland) left its Asterias Biotherapeutics Inc. Series A share count unchanged in Q4 2015.
  • Asterias Biotherapeutics Inc. Series A made up ﹤0.01% of Bellevue Asset Management (Switzerland)'s portfolio in Q4 2015, its #126 holding.
  • Bellevue Asset Management (Switzerland) first reported a position in Asterias Biotherapeutics Inc. Series A in Q1 2015 and has held it in 4 quarters since.
  • Bellevue Asset Management (Switzerland)'s Asterias Biotherapeutics Inc. Series A position peaked at $13K in Q1 2015.
  • 56 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q4 2015.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q4 2015, filed 12 Feb 2016.